Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

ClinicalTrials.gov ID: NCT01159912

Public ClinicalTrials.gov record NCT01159912. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Double-dummy, Placebo Controlled (With Rescue Medication), Multicenter Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.

Study identification

NCT ID
NCT01159912
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
350 participants

Conditions and interventions

Conditions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2010
Primary completion
Dec 31, 2011
Completion
Jan 15, 2012
Last update posted
Nov 8, 2017

2010 – 2012

United States locations

U.S. sites
55
U.S. states
22
U.S. cities
48
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35209
GSK Investigational Site Montgomery Alabama 36106
GSK Investigational Site Green Valley Arizona 85614
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site Bakersfield California 93301
GSK Investigational Site Encinitas California 92024
GSK Investigational Site Fresno California 93720
GSK Investigational Site Huntington Beach California 92647
GSK Investigational Site Long Beach California 90808
GSK Investigational Site Long Beach California 90813
GSK Investigational Site Newport Beach California 92663
GSK Investigational Site Orange California 92868
GSK Investigational Site Riverside California 92506
GSK Investigational Site Rolling Hills Estates California 90274
GSK Investigational Site San Diego California 92103-8415
GSK Investigational Site San Diego California 92120
GSK Investigational Site San Diego California 92123
GSK Investigational Site San Diego California 92128
GSK Investigational Site San Jose California 95117
GSK Investigational Site Cutler Bay Florida 33189
GSK Investigational Site Edgewater Florida 32132
GSK Investigational Site Miami Florida 33155
GSK Investigational Site Miami Florida 33185
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Albany Georgia 31707
GSK Investigational Site Columbus Georgia 31904
GSK Investigational Site Shiloh Illinois 62269
GSK Investigational Site Lenexa Kansas 66215
GSK Investigational Site Owensboro Kentucky 42301
GSK Investigational Site Metairie Louisiana 70006
GSK Investigational Site Sunset Louisiana 70584
GSK Investigational Site Baltimore Maryland 21236
GSK Investigational Site Columbia Missouri 65203
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Bellevue Nebraska 68123-4303
GSK Investigational Site Las Vegas Nevada 89119
GSK Investigational Site Shelby North Carolina 28152
GSK Investigational Site Canton Ohio 44718
GSK Investigational Site Dayton Ohio 45459
GSK Investigational Site Franklin Ohio 45005
GSK Investigational Site Oklahoma City Oklahoma 73103
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Collegeville Pennsylvania 19426
GSK Investigational Site Pittsburgh Pennsylvania 15241
GSK Investigational Site Greenville South Carolina 29607
GSK Investigational Site Orangeburg South Carolina 29118
GSK Investigational Site Austin Texas 78750
GSK Investigational Site Dallas Texas 75225
GSK Investigational Site Houston Texas 77054
GSK Investigational Site Kerrville Texas 78028
GSK Investigational Site San Antonio Texas 78224
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site San Antonio Texas 78251
GSK Investigational Site Waco Texas 76712
GSK Investigational Site Richmond Virginia 23225

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

Recently updated Asthma trials

Other public records listing Asthma. Sorted by last update posted; newest first. Not a recommendation.

All Asthma trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01159912, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01159912 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →